An international investigator-led phase III multi arm multi stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. NCT03288532
A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti−PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing metastasis following nephrectomy. NCT03024996
A phase 3 randomized study comparing nivolumab and ipilimumab combination vs placebo in participants with localized renal cell carcinoma who underwent radical or partial nephrectomy and who are at high risk of relapse. NCT03138512
A phase 3 randomized study comparing perioperative nivolumab vs observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER RCC). NCT03055013
Brahmer JR et al; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36(17):1714-68. Abstract
Cella D et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): A randomised, phase 3 trial. Lancet Oncol 2019;20(2):297-310. Abstract
Choueiri TK et al. Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Proc ASCO 2019;Abstract 101.
Choueiri TK et al. Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Genitourinary Cancers Symposium;Abstract 544.
Curti BD. Immunotherapy in advanced renal cancer — Is cure possible? N Engl J Med 2018;378(14):1344-5. Abstract
Escudier B. Combination therapy as first-line treatment in metastatic renal-cell carcinoma. N Engl J Med 2019;380(12):1176-8. Abstract
Gao J et al. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). Proc ASCO 2019;Abstract 4501.
Méjean A et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population. Proc ASCO 2019;Abstract 4508.
Méjean A et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379(5):417-27. Abstract
Motzer RJ et al; JAVELIN Renal 101 trial investigators. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103-15. Abstract
Motzer RJ et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277-90. Abstract
Pilié PG, Jonasch E. Durable complete response in renal cell carcinoma clinical trials. Lancet 2019;393(10189):2362-4. Abstract
Rini BI et al. Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. Proc ASCO 2019;Abstract 4512.
Rini BI et al; IMmotion151 Study Group. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomized controlled trial. Lancet 2019;393(10189):2404-15. Abstract
Rini BI et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. Proc ASCO 2019;Abstract 4500.
Rini BI et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116-27. Abstract
Safety and efficacy study of pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy (KEYNOTE-564). NCT03142334
Sinibaldi VJ et al. Kidney cancer: Toxicity management, symptom control, and palliative care. J Clin Oncol 2018;[Epub ahead of print]. Abstract
Tannir NM et al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). Genitourinary Cancers Symposium 2019;Abstract 547.
Thompson JA et al. Management of immunotherapy-related toxicities, Version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019;17(3):255-89. Abstract